A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples